CJC-1295 With DAC

CJC-1295 with DAC is a synthetic analogue of growth hormone-releasing hormone (GHRH) developed by ConjuChem. It is the first 29 amino acids of human GHRH with four amino-acid substitutions, plus an extra lysine carrying a reactive linker, the "drug affinity complex" (DAC). Once in the blood, the linker bonds the peptide to albumin, a blood protein. In rats it was found attached to albumin and was still in plasma beyond 72 hours (Jetté et al., Endocrinology 2005). In healthy adults, two randomised, placebo-controlled, double-blind trials found that a single dose raised growth hormone (GH) for six days or more and IGF-1 for 9 to 11 days, with an estimated half-life of about six to eight days (Teichman et al., JCEM 2006). A follow-up study in a small group of healthy young men found that GH pulses were preserved while GH levels between pulses rose. The human evidence is a handful of short studies in healthy volunteers that measured hormone levels, not clinical outcomes, and long-term safety is unknown. Neither version of CJC-1295 is approved as a medicine by the US FDA or the European Medicines Agency. It is a different compound from CJC-1295 without DAC (Modified GRF 1-29), which has no albumin-binding linker. Supplied for laboratory research use only.